FY2025 Earnings Forecast for Alector Issued By HC Wainwright

Alector, Inc. (NASDAQ:ALEC) – Analysts at HC Wainwright boosted their FY2025 EPS estimates for Alector in a report released on Monday, November 10th. HC Wainwright analyst A. Fein now expects that the company will post earnings of ($1.39) per share for the year, up from their previous estimate of ($1.64). HC Wainwright has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for Alector’s current full-year earnings is ($1.88) per share. HC Wainwright also issued estimates for Alector’s Q4 2025 earnings at ($0.34) EPS, FY2026 earnings at ($1.59) EPS, FY2027 earnings at ($1.61) EPS, FY2028 earnings at ($1.39) EPS and FY2029 earnings at ($1.14) EPS.

A number of other equities analysts have also recently weighed in on ALEC. BTIG Research cut Alector from a “buy” rating to a “neutral” rating in a research note on Wednesday, October 22nd. TD Cowen lowered shares of Alector from a “buy” rating to a “hold” rating in a report on Wednesday, October 22nd. William Blair downgraded shares of Alector from an “outperform” rating to a “market perform” rating in a research report on Wednesday, October 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alector in a research report on Wednesday, October 8th. Finally, Wall Street Zen downgraded shares of Alector from a “hold” rating to a “sell” rating in a research note on Friday, September 26th. One equities research analyst has rated the stock with a Buy rating, seven have given a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Reduce” and an average price target of $3.00.

Alector Stock Down 1.5%

Shares of Alector stock opened at $1.34 on Wednesday. Alector has a 12-month low of $0.87 and a 12-month high of $5.68. The firm has a market capitalization of $146.26 million, a PE ratio of -1.25 and a beta of 0.93. The company has a quick ratio of 3.76, a current ratio of 3.76 and a debt-to-equity ratio of 0.17. The stock’s fifty day moving average is $2.52 and its 200-day moving average is $1.93.

Alector (NASDAQ:ALEC) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.34) EPS for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.08. The company had revenue of $3.26 million during the quarter, compared to the consensus estimate of $3.49 million. Alector had a negative return on equity of 123.02% and a negative net margin of 156.03%. Alector has set its FY 2025 guidance at EPS.

Insider Activity at Alector

In related news, Director Paula Hammond sold 14,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 26th. The shares were sold at an average price of $2.36, for a total transaction of $33,040.00. Following the transaction, the director directly owned 74,909 shares of the company’s stock, valued at approximately $176,785.24. The trade was a 15.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 9.70% of the company’s stock.

Hedge Funds Weigh In On Alector

Institutional investors and hedge funds have recently modified their holdings of the stock. Acadian Asset Management LLC increased its stake in shares of Alector by 50.7% in the second quarter. Acadian Asset Management LLC now owns 2,170,388 shares of the company’s stock worth $3,033,000 after acquiring an additional 729,727 shares during the last quarter. Barclays PLC grew its stake in Alector by 414.4% in the third quarter. Barclays PLC now owns 873,375 shares of the company’s stock valued at $2,585,000 after purchasing an additional 703,580 shares in the last quarter. TD Asset Management Inc grew its stake in Alector by 483.3% in the second quarter. TD Asset Management Inc now owns 651,738 shares of the company’s stock valued at $912,000 after purchasing an additional 540,000 shares in the last quarter. Vestal Point Capital LP acquired a new position in Alector in the 1st quarter worth about $621,000. Finally, Jacobs Levy Equity Management Inc. raised its stake in shares of Alector by 25.9% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 1,334,032 shares of the company’s stock worth $1,641,000 after purchasing an additional 274,341 shares in the last quarter. 85.83% of the stock is currently owned by hedge funds and other institutional investors.

Alector Company Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.